UK to Lift Ban on Bitcoin ETFs This Week, Marking Historic Crypto Shift
UK will lift its four-year ban on Bitcoin ETFs this week, reported Crypto Rover on X. The relocation will enable retail investors to invest in Bitcoin via regulated channels, a significant change in the national cryptocurrency policy.
💥BREAKING:
— Crypto Rover (@rovercrc) October 5, 2025
UK IS SCHEDULED TO REMOVE IT'S BAN ON #BITCOIN ETFS THIS WEEK! pic.twitter.com/BPtelTcR3B
Background of the Ban
In January 2021, the FCA prohibited crypto ETFs to retail investors, claiming excessive volatility, fraud risks, and a lack of regulation. The inversion of the FCA is global. In January 2024, 11 spot Bitcoin ETFs approved in the U.S., spurring billions in inflows. Cryo ETFs also introduced in Hong Kong and Australia. FSMA 2023 in the UK has developed a regulatory framework to regulate digital assets, so the FCA can safely withdraw the ban.
Market Impact
Bitcoin ETFs are now available to retail investors through brokerage accounts, making them less difficult to acquire and increasing usage. Bitcoin price is projected to go up due to higher demand as the analysts anticipate increased demand like ETF launches in U.S. in 2024. There could also be entry of pension funds and hedge funds into the market which increases liquidity. By 2025, the crypto market is mature, stablecoins have exceeded $180 billion and DeFi platforms are managing trillions. The approving of ETFs in the UK makes London a business-friendly area to invest in crypto.
Risks and Challenges
The FCA can impose disclosure and prospectus censoring. There may be retail constraints and transitory fluctuations as markets adapt to new inflows. Platform approvals can be affected by delays in implementation. The decision to lift the ban will allow Bitcoin ETFs into the UK market, making it more accessible, used, and institutionalized. The relocation enhances the crypto-financial position of London with a balanced protection of investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana News Update: Sunrise Seeks to Resolve Solana's Liquidity Splintering through Immediate Listings
- Wormhole Labs launches Sunrise, a Solana-native listing platform enabling instant liquidity for new tokens like MON, addressing DeFi fragmentation. - The platform uses NTT framework to natively onboard cross-chain assets, retaining liquidity within Solana and integrating with DEXs like Orb and Jupiter. - MON's day-one trading demonstrates Sunrise's potential to solidify Solana as a hub for tokenized assets, with TVL rising 32.7% to $11.5B in Q3 2025. - Analysts highlight Sunrise's role in standardizing h
India’s Cryptocurrency Conundrum: Can Updated VDA Regulations Safeguard Progress or Hinder Expansion?
- India's VDA regulatory review aims to align crypto rules with global standards, addressing consumer protection gaps and market integrity risks. - Current fragmented regulations, including 30% profit tax and weak custody laws, have driven users to offshore platforms, stifling local innovation. - Proposed reforms include risk-based token classification, licensing for exchanges, and RWA frameworks to balance innovation with systemic risk mitigation. - A balanced approach could attract investment and strengt
Bitcoin Updates Today: Bearish Pressure Mounts, Yet Optimistic Bulls Anticipate Future Expansion
- Bitcoin's bearish technical indicators reinforce downward pressure despite short-term recovery attempts. - Ethereum and altcoins mirror Bitcoin's weakness, with $2B in crypto liquidations intensifying selling pressure. - Long-term fundamentals project $17.14B crypto market growth by 2033 driven by institutional adoption and regulatory clarity. - Thailand's Bitkub plans $200M Hong Kong IPO amid local market struggles, highlighting regional listing strategy shifts. - Persistent bearish momentum remains, wi
Biomarkers Shine, Results Disappoint: Novo's Attempt at Alzheimer's Falls Short
- Novo Nordisk's Alzheimer's trials for semaglutide failed to meet primary endpoints, causing a 9% premarket stock drop to a multi-year low. - The $3.8B trial showed no disease progression slowing despite biomarker improvements, with UBS estimating only 10% success probability beforehand. - Market ripple effects included Eli Lilly's 0.5% decline and Biogen's 2.7% rise, highlighting GLP-1 drug competition in neurodegenerative therapies. - This setback compounds Novo's challenges: 50% YTD stock decline, obes
Trending news
MoreCrypto prices
More
